AP26113 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.

CNX-2006 is an irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.

BI-4020 is a noncovalent, new-generation, wild-type EGFR sparing, macrocyclic tyrosine kinase inhibitor.

TQB3804 is the forth-generation EGFR inhibitor with IC50 values of 7.92nM,0.218nM and 0.16nM for EGFR(WT), EGFR (C797S/T790M/del19) and EGFR (L858R/T790M/C797S), respectively.

Theliatinib, is a small molecule, epidermal growth factor receptor tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities.

Avitinib selectively inhibits EGFR L858R/T790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate.

Lazertinib is a selective inhibitor of mutant EGFR with lowest activity against EGFR wild type.

Gefitinibis an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively, and interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.

In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation.

EGF816 inhibits mutant EGFR (L858R/790M) with Ki of 31 nM irreversibly and selectively.

Brigatinib is a selective ALK inhibitor with IC50 value of 0.37nM, and also inhibits ROS1, FLT3, FLT3-D835Y mutant and EGFR less potently.

AV-412 is an inhibitor of EGFR (IC50 = 0.5-2 nM), ErbB2 (IC50=19 nM), Abl receptor (IC50 = 41nM), mutant EGFR-L858R (IC50=0.51 nM) and EGFR-T790M (IC50=0.79 nM). It also inhibits autophosphorylation of EGFR and ErbB2 with IC50s of 43 nM and 282 nM, respectively.

HS-10296 is the third-generation EGFR TKIs which exhibited inhibitory effect on both EGFR-activating mutations and T790M-resistant mutation.

EAI045, an allosteric inhibitor, selectively targets drug-resistant EGFR mutants like EGFR-L858R, EGFR-T790M and EGFR-L858R/T790M with IC50 of 0.019 μM, 0.19 μM and 0.002 μM respectively.

JND3229 is a new highly potent EGFR(C797S) inhibitor with IC50 values of 5.8nM, 30.5nM and 6.8nM for EGFR (L858R/T790M/C797S), EGFR (T790M, L858R) and EGFR, respectively.